NHS Waiting List Falls Again: Why Recovery Still Needs Diagnostics
NHS England said the total waiting list decreased to 7.22 million, down 31,006 compared with January 2026 and more than 400,000 lower than in July 2024. It also said 62.6% of patients were waiting under 18 weeks, up 1.1 percentage points on the previous month.
That is a positive movement. It suggests the NHS was continuing to make progress on elective recovery despite winter pressure, record A&E demand and disruption from industrial action.
But the same April news cycle also showed why recovery cannot be judged by waiting-list totals alone. Just days before the NHS England update, the government announced £237 million of investment in 36 new, expanded or enhanced Community Diagnostic Centres to increase access to tests, checks and scans closer to home.
That matters because diagnostics are often the gateway to treatment. A patient cannot move smoothly through the system if they are still waiting for the scan, test, biopsy or specialist investigation needed to confirm what is wrong.
For patients, the message is mixed but important: the waiting list may be falling, but faster diagnosis remains central to whether NHS access actually feels better.
What happened in the news
NHS England’s April update showed progress on the elective waiting list. The number of referral-to-treatment pathways waiting to start treatment had fallen again, and the proportion of patients waiting less than 18 weeks had improved.
The figures came as NHS leaders said the service was close to its short-term elective recovery target. That target aimed to increase the share of patients waiting under 18 weeks to 65% by the end of March 2026.
At the same time, the government announced further investment in Community Diagnostic Centres. Four new centres were due to open, 17 were set to be expanded, and 15 were to receive targeted enhancements. The aim was to improve access to tests such as MRI scans, CT scans, ultrasound, blood tests, respiratory checks, audiology, ophthalmology and other diagnostic services.
Taken together, the two announcements tell the real story of NHS recovery. Reducing the treatment waiting list is essential, but the system also needs enough diagnostic capacity to find out what patients need in the first place.
Why diagnostics are so important
Diagnostics sit near the start of many patient journeys.
Someone with symptoms may need a GP appointment, referral, consultant review and then a test or scan before treatment can even be planned. That test might be an MRI, CT scan, ultrasound, endoscopy, echocardiogram, blood test, biopsy or another investigation.
If diagnostics are delayed, the whole pathway slows down. A patient may not yet be officially waiting for treatment, but they are still waiting for answers.
This is why diagnostic capacity matters so much. It affects cancer pathways, planned surgery, orthopaedics, cardiology, gynaecology, respiratory care, neurology and many other specialties.
A falling treatment waiting list is good news, but patients may not feel the benefit if they are still stuck before diagnosis.
Why waiting-list improvement can feel slow to patients
National waiting-list numbers can move in the right direction without every patient feeling immediate improvement.
A patient waiting for a hip operation may care about elective treatment capacity. A patient with possible cancer symptoms may care about urgent diagnostic tests. A patient with chest symptoms may need cardiology checks. A patient with abdominal symptoms may need endoscopy or imaging before anyone knows whether treatment is needed.
This means different parts of the system can improve at different speeds. Some people may be seen faster, while others still experience long waits depending on location, specialty and the type of test or treatment needed.
That is why a falling waiting list should be welcomed, but not treated as the whole story.
What Community Diagnostic Centres are meant to do
Community Diagnostic Centres are designed to move more tests and scans out of acute hospital settings and into local hubs.
The idea is simple: if people can access diagnostics closer to home, hospitals may be under less pressure, appointments may be more convenient, and patients may get answers sooner.
The April funding announcement included new centres, expanded centres and targeted upgrades to existing sites. Some centres were expected to receive new scanning equipment, clinic rooms or additional services. The government said the investment would help patients access tests more quickly and reduce the need to travel to hospital.
For patients, this matters because diagnosis often feels like the bottleneck. If more capacity is available locally, it may help shorten the time between symptoms, referral, investigation and treatment decision.
What this means for PMI buyers
For people comparing private medical insurance, the diagnostics story is highly relevant.
Many buyers focus on hospital treatment, but the first real value of PMI may be earlier in the pathway. If a policy includes outpatient consultations and diagnostic tests, it may help with eligible private investigations such as MRI scans, CT scans, ultrasound or specialist assessment.
That can matter when someone is worried about unexplained symptoms and wants answers sooner.
But policy details are crucial. Not every PMI policy includes strong outpatient or diagnostic cover. Some cheaper policies may limit outpatient consultations, exclude certain tests, cap scans, require insurer authorisation or only cover diagnostics in specific circumstances.
That means a low-cost policy may not solve the access problem the buyer actually cares about.
Why cheap PMI can disappoint on diagnostics
Cheap PMI can be useful for some people, but it needs careful reading.
A budget policy may reduce premiums by limiting outpatient care, restricting hospital choice, adding a larger excess or excluding certain benefits. That may be acceptable if the buyer mainly wants cover for eligible inpatient or day-patient treatment.
But if the buyer’s main concern is getting a diagnosis, weak outpatient cover can be a problem.
For example, a policy may cover surgery after a diagnosis but provide limited support for the consultant appointments and scans needed to reach that diagnosis. In that situation, the buyer may still need to use the NHS or self-fund private diagnostics before the policy becomes useful.
This is why diagnostics should be checked before price.
What to check before buying PMI
If faster diagnosis is one of your reasons for comparing PMI, ask direct questions.
Does the policy include outpatient consultations? Are MRI scans covered? Are CT scans covered? Are ultrasound scans covered? Are blood tests included? Are endoscopy or other investigations covered? Is there an outpatient limit? Do scans count towards that limit? Is GP referral required? Does the insurer need to authorise tests first? Are pre-existing symptoms excluded? Which hospitals and diagnostic centres are included?
It is also worth asking how the policy handles cancer investigations, because suspected cancer pathways may involve several stages of testing before treatment begins.
The aim is to understand whether the policy helps with the point where you are most likely to feel stuck.
What PMI cannot solve
Private medical insurance is not a full replacement for the NHS. It does not usually replace emergency care, ambulance services, A&E, chronic condition management, public health services or routine NHS screening programmes.
It may also exclude pre-existing conditions, existing symptoms, referrals already underway or investigations that started before the policy began.
That means someone already waiting for a scan or specialist review should not assume they can buy PMI and immediately claim for the same issue. The insurer may treat that as pre-existing.
PMI is best understood as cover for future eligible private healthcare needs, not a way to move an existing NHS wait into the private system after symptoms have already started.
What patients should take from the news
The April waiting-list figures were encouraging. A falling waiting list is better than a rising one, and more patients waiting under 18 weeks is a positive sign.
But the diagnostic investment announced in the same month shows where the pressure still sits. The NHS needs more capacity to diagnose patients quickly, not just more capacity to treat them once a diagnosis is confirmed.
For Find Me PMI readers, the practical lesson is clear: when comparing private medical insurance, do not only look at hospital treatment. Look closely at outpatient and diagnostic cover, because that may be where the policy matters most.
Related guides
- [Treatment Access Index]
- [Elective Care and NHS Waiting Lists]
- [Diagnostics and NHS Waiting Times]
- [Does PMI Cover Scans Like MRI and CT?]
- [What Level of Private Medical Insurance Cover Do I Need?]
- [Is Cheap PMI Worth It?]
- [Compare Private Medical Insurance Quotes]
The bottom line
The NHS waiting list fell again in February 2026, showing continued progress on elective recovery.
But recovery still depends heavily on diagnostics. Patients need timely tests, checks and scans before treatment can be planned.
That is why diagnostics deserve their own place in the Treatment Access Index, and why PMI buyers should check outpatient and scan cover carefully before choosing a policy.
